Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.76)
# 2,000
Out of 5,044 analysts
52
Total ratings
32.65%
Success rate
2.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Initiates: Overweight | $18 | $8.38 | +114.80% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.55 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $2.36 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $53.94 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $29.36 | +240.60% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $4.61 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $9.44 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.74 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $10.96 | - | 1 | Dec 9, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $3.19 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.80 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $33.82 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $9.53 | -47.53% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.26 | +475.22% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $15.76 | -49.24% | 1 | Mar 20, 2023 |
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $8.38
Upside: +114.80%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.55
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.36
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $53.94
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $29.36
Upside: +240.60%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.61
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.44
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.74
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.96
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.19
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.80
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $33.82
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $9.53
Upside: -47.53%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.26
Upside: +475.22%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $15.76
Upside: -49.24%